Evening Primrose Oil for Eczema: Why the Trial Results Differ

Evening primrose oil for eczema has conflicting trial findings, but it is not an established treatment. NCCIH reports that oral evening primrose oil has not been shown helpful for atopic dermatitis symptoms. A later positive trial in mild disease does not turn that overall answer into a guarantee. The useful question is which outcome improved, in whom, and against what comparison.

NCCIH: evening primrose oil · 2018 randomized trial · Sources checked September 23, 2026.

The review was not 27 trials of evening primrose oil

The 2013 Cochrane review included 27 trials and 1,596 participants across evening primrose oil and borage oil combined. Nineteen trials studied evening primrose oil; eight studied borage oil. Neither oil showed a statistically significant overall advantage over placebo. The review assessed oral use, not creams.

Its searches ran through August 2012. That date matters: the review could not include a trial published in 2018. Calling the later study proof that the review misreported its included trials would confuse a new piece of evidence with the evidence available at the earlier cutoff. This is a comparison of publication scope, not a new pooled analysis.

Cochrane review: methods and results · Later trial publication · Sources checked September 23, 2026.

The positive result was narrower than a claim of repaired skin

The Korean randomized, double-blind trial enrolled 50 people with mild atopic dermatitis, defined by an Eczema Area and Severity Index (EASI) score of 10 or below. Capsules contained 450 mg of evening primrose oil, including 40 mg of gamma-linolenic acid (GLA); comparison capsules contained 450 mg of soybean oil. Treatment lasted four months. These are capsule contents, not a daily-dose instruction.

At month four, the EASI comparison favored evening primrose oil. However, changes in transepidermal water loss and skin hydration did not reach statistical significance. Our evidence distinction: an improved clinical severity score and a demonstrated improvement in these barrier measurements are separate claims. This trial supports reporting the former result; it does not establish the latter.

2018 trial abstract: population, formulation and outcomes · Sources checked September 23, 2026.

Earlier trials did not all point in the same direction

A 1993 placebo-controlled trial recruited 123 people; 102 completed it. It compared evening primrose oil, evening primrose oil with fish oil, and placebo over 16 weeks. Neither active treatment showed an advantage in the reported assessments, which included clinical severity, topical steroid requirements and patient symptoms.

A 2008 trial reported a different result: improvement in 24 of 25 evening-primrose recipients versus eight of 25 placebo recipients over five months. Its abstract says the analysis took the first 25 completers from each group. That is a selected completer comparison, not a result that can simply be assigned to every person originally enrolled. The capsules were 500 mg of evening primrose oil versus 300 mg of sunflower oil. The abstract does not establish a daily regimen.

The comparisons therefore differ in more than their conclusion: comparator oils, follow-up periods and analysis populations differ. These reports are not interchangeable repetitions of the same experiment. We have not combined their counts into an effectiveness percentage.

1993 randomized trial · 2008 trial abstract · Sources checked September 23, 2026.

What the evidence leaves unresolved

NCCIH lists abdominal pain, nausea and diarrhea among common oral side effects and notes that less is known about safety in children. Medication interactions and pregnancy or breastfeeding require discussion with a healthcare professional. A plant-derived oil is not automatically suitable for a particular person.

For an evening-primrose claim, retain the study date, oral or topical route, oil and GLA quantities, comparison treatment, analysis population and named outcome. Missing information stays missing. A capsule label cannot supply the trial's unreported daily schedule, and an oral study cannot validate an eczema cream.

NCCIH: safety · 2018 trial formulation · Cochrane: oral-treatment scope · Sources checked September 23, 2026.

Reviewed September 23, 2026. Educational analysis; not individualized medical advice.

Ingredient evidence: vitamin D · fish oil · probiotics.